



## Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*


Monaldi Arch Chest Dis 2025 [Online ahead of print]

*To cite this Article:*

Gelardi M. **Chronic rhinosinusitis with nasal polyps: 64 pheno-endotypes for personalized therapy. Time to change the paradigm.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2025.3645

*Submitted: 12-07-2025*

*Accepted: 26-12-2025*

 ©The Author(s), 2025  
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

**Chronic rhinosinusitis with nasal polyps: 64 pheno-endotypes for personalized therapy.  
Time to change the paradigm**

Matteo Gelardi

Otorhinolaryngology Unit, University of Foggia, Italy

**Correspondence:** Matteo Gelardi, Otorhinolaryngology Unit, University of Foggia, Italy-  
E-mail: [matteo.gelardi@unifg.it](mailto:matteo.gelardi@unifg.it)

**Key words:** CRSwNP, nasal cytology, clinical-cytological grading, type 2 inflammation, endotyping.

**Conflict of interest:** the author declares no competing interests.

**Ethics approval and consent to participate:** not applicable.

**Informed consent:** not applicable.

**Patient consent for publication:** not applicable.

**Availability of data and materials:** not applicable.

**Funding:** none.

Dear Editor,

Chronic rhinosinusitis with nasal polyps (CRSwNP) is still often considered, both in clinical practice and in the literature, as a homogeneous entity. Yet, nasal polyposis is not all the same — in fact, one might say these are not “polyps” in the strict pathological sense [1-3].

Using the Clinical-Cytological Grading (CCG) approach [1], which crosses 4 clinical phenotypes (ASA sensitivity, asthma, allergy, ASA+asthma) with 4 cytological endotypes (neutrophilic, mast cell, eosinophilic, eosinophilic-mast cell), 64 different pheno-endotypes emerge, each with its own recurrence prognostic index. Naturally, adding molecular and clinical parameters could reveal even more [4]. This compels a radical shift in paradigm: there is not one disease, but many forms, each with a distinct biological and clinical narrative.

In this context, nasal cytology is a fundamental diagnostic tool [1,5]. It allows for the identification of mast cell cytotypes, often associated with more severe, refractory forms, which traditional pathology frequently misses. Routine hematoxylin-eosin staining does not highlight mast cells, leading to systematic underestimation. Nasal cytology has unveiled an entire “hidden world” of nasal inflammation — and is now even awakening the interest of pathologists, in close cooperation with cytologists, as shown in a recent study [2].

From a terminology standpoint, it is time for clarity. The EPOS guidelines, from the early versions to the 2023 update [6], have progressively renamed the condition as “chronic rhinosinusitis with nasal polyps” — a longer but not necessarily more precise label. It might have been better to go in the opposite direction: to abandon the word 'polyposis', now inaccurate, and instead use a term that reflects its real pathophysiology: Chronic Hyperplastic Rhinosinusitis [7].

This is not mere semantics: it is rooted in the general pathology we all studied in our first years of medical school. True polyps, by definition, have a fibrovascular axis and, once removed, do not recur. These nasal formations, wrongly called “polyps,” do recur — because they are the manifestation of chronic hyperplastic mucosal inflammation, now more precisely defined immunologically as “Type 2 inflammation” [3,5]. A condition dominated by eosinophils, mast cells, and interleukins IL-4, IL-5, and IL-13, paving the way to new nosology and therapeutic strategies.

This terminological confusion dates back to Hippocrates, who — let me joke — hadn't yet taken his general pathology exam [7], and misnamed these mucosal growths. We, on the other hand, have passed that exam, and should finally name things properly, guided by modern science.

The future of CRSwNP lies in personalized therapy — not just guided by molecular markers but also by clinical and cytological profiling. A truly multidisciplinary approach that involves ENT

specialists, allergists, pulmonologists, immunologists — and finally gives this condition the nosological dignity it deserves.

Moreover, improper stratification of the disease leads to inappropriate treatments and significant economic burden for the healthcare system. The use of expensive biologics should follow objective, stratified criteria — otherwise we risk both under- and overtreatment [4]. Only with precise phenotyping can we ensure therapeutic appropriateness, economic sustainability, and real clinical benefit for the patient.

## References

1. Gelardi M, Iannuzzi L, Quaranta N, et al. Nasal cytology: practical aspects and clinical relevance. *Clin Exp Allergy* 2016;46:785-92.
2. Gelardi M, Giancaspro R, Duda L, et al. Eosinophil-mast cell pattern of intraepithelial infiltration as a marker of severity in CRSwNP. *Sci Rep* 2023;13:12101.
3. Gelardi M, Cassano M, Ciprandi G. Clinical relevance of cytological grading in CRSwNP. *J Allergy Clin Immunol* 2020;146:462-3.
4. Gelardi M, Giancaspro R, Quaranta VN, et al. Dupilumab's impact on nasal cytology: real life experience after 1 year. *Am J Otolaryngol* 2024;45:104275.
5. Gelardi M, Netti GS, Giancaspro R, et al. Galectin-10 and cytological grading in CRSwNP. *Am J Rhinol Allergy* 2022;36:229-37.
6. Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on biologics in CRSwNP. *Rhinology* 2023;61:194-202.
7. Dianzani MU. *General pathology*. First edition. Turin, Italy: UTET; 1974.